Gate News reports that on March 20, biopharmaceutical company Acurx Pharmaceuticals (Nasdaq: ACXP) approved a $10 million Bitcoin purchase plan aimed at leveraging Bitcoin’s anti-inflation properties to hedge against long-term R&D funding devaluation and achieve financial diversification.
Investment management software company Enfusion (NYSE: ENFN) plans to allocate 10% of its excess cash into Bitcoin and Ethereum to enhance risk-adjusted returns. Additionally, Nature’s Miracle (Nasdaq: NMHI) launched a $5 million Bitcoin reserve program, marking its inclusion of cryptocurrency as a reserve asset.
A crypto custody service provider reported a 40% year-over-year growth in its crypto custody services, reflecting increasing reliance of non-crypto enterprises on compliant custodians to enter the Bitcoin market.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
